Cargando…
Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?
The imbalance between BCL-2 homologues and pro-death counterparts frequently noted in cancer cells endows them with a cell autonomous survival advantage. To eradicate ectopic cells, inhibitors of these homologues (BH3 mimetics) were developed to trigger, during anticancer treatment, full activation...
Autores principales: | Barillé-Nion, Sophie, Lohard, Steven, Juin, Philippe P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464802/ https://www.ncbi.nlm.nih.gov/pubmed/32722518 http://dx.doi.org/10.3390/biom10081109 |
Ejemplares similares
-
Bcl-xL controls a switch between cell death modes during mitotic arrest
por: Bah, N, et al.
Publicado: (2014) -
Bcl-xL controls a switch between cell death modes during mitotic arrest
por: Bah, N, et al.
Publicado: (2014) -
Survivin contributes to DNA repair by homologous recombination in breast cancer cells
por: Véquaud, Eloïse, et al.
Publicado: (2015) -
γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
por: Séveno, Céline, et al.
Publicado: (2012) -
YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network
por: Véquaud, Eloïse, et al.
Publicado: (2015)